99mTechnetium Sestamibi-123Iodine Scintigraphy Is More Accurate Than 99mTechnetium Sestamibi Alone before Surgery for Primary Hyperparathyroidism by Ryhänen, Eeva M. et al.
Research Article
99mTechnetium Sestamibi-123Iodine Scintigraphy Is More
Accurate Than 99mTechnetium Sestamibi Alone before Surgery
for Primary Hyperparathyroidism
Eeva M. Ryhänen,1 Jukka Schildt,2 Ilkka Heiskanen,3 Mika Väisänen,3 Aapo Ahonen,2
Eliisa Löyttyniemi,4 Camilla Schalin-Jäntti,1 and Matti J. Välimäki1
1Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, University of Helsinki,
00029 Helsinki, Finland
2HUS Medical Imaging Center, Department of Clinical Physiology and Nuclear Medicine, Helsinki University Central Hospital,
00029 Helsinki, Finland
3Department of Surgery, Helsinki University Central Hospital, 00029 Helsinki, Finland
4Department of Biostatistics, University of Turku, 20520 Turku, Finland
Correspondence should be addressed to Camilla Schalin-Ja¨ntti; camilla.schalin-jantti@hus.fi
Received 28 September 2014; Revised 14 December 2014; Accepted 19 December 2014
Academic Editor: Irene J. Virgolini
Copyright © 2015 Eeva M. Ryha¨nen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Objectives. Studies comparing outcome of single-99mTc-methoxyisobutylisonitrile (99mTc-sestamibi) and dual-tracer 99mTc-
sestamibi scintigraphy in combination with 123I before primary surgery of primary hyperparathyroidism (PHPT) are scarce.
Methods. We compared 99mTc-sestamibi/123I and 99mTc-sestamibi in a single-centre retrospective series of 269 PHPT patients. The
results were related to laboratory, surgical and histological findings. Results. 99mTc-sestamibi/123I and 99mTc-sestamibi were positive
in 206 (76.6%) and 111 (41.3%) of 269 patients, respectively (P < 0.001). Accuracies for 99mTc-sestamibi/123I and 99mTc-sestamibi
were 63.4% and 34.9%, respectively (96% CI, P < 0.001). Prevalence of multiglandular disease was 15.2%. In multiglandular disease,
99mTc-sestamibi/123I and 99mTc-sestamibi revealed 43.8 and 22.1% of pathological glands, respectively (P < 0.001). Cure rate was
similar for patients with (191/206; 92.7%) and without (59 of 63; 93.7%) a positive 99mTc-sestamibi/123I finding. Duration of targeted
surgery (one or two quadrants) was 21 and 15 minutes shorter than bilateral neck exploration, respectively (both P < 0.001). Higher
serum calcium (P = 0.014) and PTH (P = 0.055) concentrations and larger tumours (P < 0.001) characterized the 206 patients with a
positive preoperative scan who were cured by removal of a single adenoma. Conclusions. 99mTc-sestamibi/123I scintigraphy is more
accurate than 99mTc-sestamibi before surgery of PHPT. However, outcome of surgery is not determined by scintigraphy alone.
1. Introduction
Bilateral neck exploration (BNE) with identification of all
four parathyroid glands and with removal of the abnormal
gland(s) has been the surgical gold standard for treatment
of primary hyperparathyroidism (PHPT). In experienced
hands, it is successful in more than 95% of cases with-
out any preoperative imaging [1]. However, as 80 to 85%
of patients with PHPT have single-gland disease, targeted
surgery such as unilateral neck exploration (UNE) or mini-
mally invasive parathyroidectomy (MIP) may be considered.
Focal approaches are favoured by shorter operation times
and reduced risk of complications, the major one being
recurrent laryngeal nerve palsy. Preoperative imaging studies
are mandatory if the surgeon opts for focal procedures. The
two main reasons for failed surgery are ectopic glands and
undetected multiglandular disease, which is present in about
15% of PHPT patients [2]. Therefore, a major challenge in
order to avoid inadequate surgery is accurate preoperative
imaging of multiglandular disease [2].
Ideally, preoperative imaging should accurately identify
on which side of the neck the pathological parathyroid
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gland(s) reside, without false positive findings on the healthy
side. As introduced by Coakley et al. in 1989 [3], 99mTc
methoxyisobutylisonitrile (99mTc-sestamibi) scintigraphy has
since gained great popularity and is worldwide probably
the most common imaging technique used before primary
surgery of PHPT. 99mTc-sestamibi is used either alone or in
combination with 123iodine (123I) or 99mtechnetium pertech-
netate (99mTcO
4
−) for subtraction of the thyroid image,
as uptake of 99mTc-sestamibi is not tissue specific. 99mTc
is sequestered within mitochondria in both thyroid and
parathyroid glands, salivary tissue, and normal cardiac cells
[2, 4, 5]. Imaging with the single-tracer technique is based
on the different washout kinetics for thyroid and parathyroid
tissue. Maximum thyroid gland activity is reached within
five minutes while parathyroid activity is sustained with
delayed washout, allowing for acquisition of the parathyroid
glands two hours after injection [6]. Thyroid nodules may
have a prolonged washout time and cause false-positive
findings in single-tracer scintigraphy with 99mTc-sestamibi
[2]. The dual-tracer technique is performed in combina-
tion with 123I or 99mTc, which are taken up by thyroid
tissue only. The 123I or 99mTc thyroid image is thereafter
digitally subtracted from the 99mTc-sestamibi image, allow-
ing for visualization of parathyroid tissue alone [6]. Some
studies compared the sensitivity and specificity of neck
ultrasound and 99mTc-sestamibi scintigraphy for revealing
hyperfunctioning parathyroid glands, demonstrating similar
performance [7]. A preoperative study in 15 PHPT patients
comparing the performance of 99mTc-sestamibi SPECT with
99mTc-sestamibi/123I SPECT suggested that the double-tracer
technique performs better [6] and a series of 37 PHPT
patients also concluded that imaging with the dual-tracer
protocol is more accurate than imaging with a single tracer
[8]. Despite being widely used, single centre studies compar-
ing the performance of 99mTc-sestamibi/123I to that of 99mTc-
sestamibi alone in large patients series referred for surgery of
primary PHPT are scarce.
At our centre, routine preoperative 99mTc-sestamibi
scintigraphy has been performed for more than 15 years.
We used the single-tracer technique up to November 2006,
whereafter the double-tracer 99mTc-sestamibi/123I technique
was introduced. The aim of the present study was to retro-
spectively compare the performance of these two techniques
in 269 consecutive patients who underwent primary surgery
at our centre during years 2006–2009 because of primary
PHPT.
2. Patients and Methods
2.1. Patients. FromNovember 2006 throughNovember 2009,
543 consecutive patients were referred for evaluation of
surgery because of suspected PHPT to the Helsinki Uni-
versity Hospital. All patients underwent parathyroid scintig-
raphy at the Helsinki University Hospital Medical Imaging
Center, Department of Clinical Physiology and Nuclear
Medicine. From this original cohort we excluded patients
suffering from secondary or tertiary hyperparathyroidism
534 HPT patients referred for
123I-99mTc-sestamibi scintigraphy
269 patients with PHPT
referred for primary surgery
123I-99mTc-sestamibi
negative N = 63
123I-99mTc-sestamibi
positive N = 206
N(1 focus) = 193, N(2 focuses) = 13
Surgery:
MIP = 14
UNE = 145
BNE = 47(22.8%)
Surgery:
MIP = 1
UNE = 6
BNE = 56(88.9%)
Cured:
59/63
93.7%
Cured:
191/206
92.7%
Figure 1: Flow chart of 534 patients referred for 99mTc-sestamibi/123I
scintigraphy because of hyperparathyroidism (HPT). MIP: mini-
invasive parathyroidectomy; UNE: unilateral exploration; BNE:
bilateral exploration.
and patients who were not operated on (Figure 1). Further
exclusion criteria were patients referred for reoperation of
PHPT and patients suffering from MEN-1 syndrome. The
final patient series comprised 269 subjects who all fulfilled the
biochemical criteria for PHPT and also fulfilled the criteria
for operative treatment of PHPT [9].
The multiglandular disease (MGD) group was defined
as the patients who were not cured by removal of one
abnormal parathyroid gland and patients from whom two
or more pathological glands were surgically removed. The
number of pathological glands in uncured MGD patients
was estimated by adding one gland to the total number of
abnormal glands removed. Short-term remission (normal
serum calcium and at least 50% decrease in serum PTH
concentrations) was evaluated. The study was conducted
according to the guidelines of theDeclaration ofHelsinki.The
protocol was approved by an institutional board review.
2.2. Scintigraphy. Patients fasted for two hours before the
study. A 123I-iodide capsule of 13–15MBq was adminis-
tered orally 3 hours before the 123I-imaging. Immediately
thereafter, 790–940MBq of 99mTc-MIBI was intravenously
injected and data acquisition started in 5 minutes. A double-
windowprocedurewas used to acquire simultaneous imaging
of both radiopharmaceuticals. Late imaging with a similar
double-window procedure was performed two hours after
the first imaging. A subtraction procedure, in which 123I
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images were subtracted from 99mTc-MIBI images by means
of manually drawn regions of interest (ROI), was performed
for both early and late imaging. Dual-phase MIBI technique
comprised early and late 99mTc-MIBI images.
The imaging was performed with a triple-head Picker
Prism 3000XP gamma camera (Cleveland, OH, USA)
equipped with a Picker Odyssey FX Computer. A low energy
general all-purpose collimator was used for imaging. The
image matrix was 256×256. Window settings were 140 keV ±
8% for 99mTc and 159 keV ± 7% for 123I.
A focally increased activity in 99mTc-MIBI images and
an abnormal washout and residual uptake on subtraction
images were interpreted as a positive finding. The location
of the abnormal uptake was reported. To confirm the quality
of original scintigraphy findings, all images were blindly
reevaluated by two experienced nuclear medicine physicians
(Jukka Schildt and Aapo Ahonen). If their opinions differed,
they evaluated the images together to reach a consensus.
The findings were divided into four different categories:
normal, equivocal, slightly suspicious, and abnormal. For
data analyses, equivocal findings were considered negative.
In 13 patients (4.8%) the reevaluation differed from the
original 99mTc-sestamibi/123I scintigraphy reviews, which
guided the operation andwere used in the analyses.TheMIBI
alone reviews were obtained from the reevaluation of the
images.
Per-patient based scintigraphy was considered accurate
if the lesion(s) detected by the localization technique were
surgically removed and were histologically confirmed to be
adenoma, hyperplasia, or carcinoma, and the patient was
biochemically cured. Findings that were not verified on
surgery or histologically or findings that did not result in
biochemical cure after operation of the corresponding site
were considered not accurate. As all patients had biochemical
evidence of the disease, negative preoperative localization
studies were considered false negative, that is, not accurate.
2.3. Surgery. The type of surgery was chosen on the basis
of the 99mTc-sestamibi/123I review available at the time of
surgery and clinical data. Any condition indicating hyper-
plasia favoured bilateral neck exploration (BNE). BNE was
performed through Kocher’s suprajugular incision, with an
attempt to identify all four parathyroid glands and remove
obviously enlarged and pathological ones. In the unilateral
scan-directed approach (UNE), only the side of the expected
pathological parathyroid gland was dissected [10]. Focused
parathyroidectomy was performed either through standard
Kocher’s suprajugular incision or a minimal skin incision
(<25mm) with excision of a solitary parathyroid tumor;
further dissection to identify another ipsilateral parathyroid
gland was not performed. In open minimal invasive parathy-
roidectomy (MIP) an incision was made anterolaterally close
to the site of the suspected parathyroid adenoma. If an
abnormal parathyroid gland was not found in the scan-
positive location, another ipsilateral gland was exposed and
removed if clearly enlarged. When necessary, a focused min-
imal invasive procedure was converted to BNE. In equivocal
cases, a frozen sample was examined by a pathologist before
completing the operation. Intraoperative PTHmeasurements
were not used.
2.4. Statistics. For biochemically cured patients the com-
parisons between those with a single adenoma detected or
not detected on preoperative 99mTc-sestamibi/123I scan were
performed using the Wilcoxon rank sum test or the chi-
square test. McNemar’s and Fisher’s exact tests were used to
compare operative and imaging findings and the accuracy
between 99mTc-sestamibi/123I and 99mTc-sestamibi scans.The
duration of the operative procedures was log-transformed
before comparison according to the type of surgery with
one-way analysis of variance. Pairwise comparisons between
the different types of surgery were performed with Tukey’s
method. A 𝑃 value less than 0.05 was considered statistically
significant. All tests were performed as two-sided tests. S+
Software, version 8.1, was used for statistical analyses.
3. Results
A flow chart of the study is depicted in Figure 1. Baseline
characteristics of the 269 study subjects are given in Table 1.
99mTc-sestamibi/123I revealed one (𝑛 = 193) or two (𝑛 =
13) positive findings in 206 patients (76.6%). 99mTc-sestamibi
alone revealed significantly fewer focuses, one (𝑛 = 102)
and two (𝑛 = 9) in 111 patients (41.3%; 𝑃 < 0.001).
In two patients lesions were detected by 99mTc-sestamibi
alone. Unilateral operation was performed in 166 patients;
97 operations were targeted to one quadrant, 54 operations
were targeted to two quadrants, and 15 operations were
minimally invasive parathyroidectomy. One hundred and
three patients underwent bilateral neck exploration (38.2% of
study patients). Bilateral neck exploration was performed in
88.9% of patients with negative preoperative imaging and in
22.8% with positive preoperative imaging results.
3.1. Outcome of Surgery. Two hundred and forty-nine
patients (92.5%) were cured by removal of pathological
parathyroid glands. In addition, one patient was biochemi-
cally cured after removal of a retrosternal goiter, although the
abnormal parathyroid gland(s) was not identified at surgery.
The cure rate was similar for patients with (191 of 206;
92.7%) and without (59 of 63; 93.7%) a positive finding on
99mTc-sestamibi/123I (𝑃 = NS) (Figure 1). Surgery was not
successful in 19 patients. Sixteen failures (84.2%) were related
to multiglandular disease and in three cases no abnormal
parathyroid gland was found. Twelve, three, and four of the
19 patients had unilateral, bilateral, or no finding on 99mTc-
sestamibi/123I scintigraphy, respectively.
3.2. Comparison of Scintigraphic and Surgical Findings
3.2.1. Accuracy. Overall accuracies of the whole study popu-
lation (95% CI) for 99mTc-sestamibi/123I and 99mTc-sestamibi
were 63.4% (57.4–69.0) and 34.9% (29.2–40.6), respectively
(𝑃 < 0.001) (Table 2). For the whole cohort, accuracies for
detection of one abnormal parathyroid gland were 60.9%
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183 patients
with a TP finding
164 cured patients 
with an accurate
 scan finding
9 cured patients with
 one TP finding and 
one FN finding on 
the contralateral side
9 uncured patients
with one TP finding
 and obviously one 
FN finding as
 PHPT continued
1 uncured patient 
with a TP finding, and
 also a FN finding (2
 pathological ipsilateral 
glands removed)
10 patients
with a FP finding
8 cured patients with
one operation finding 
on the contralateral 
side
1 FP finding 
confirmed at
 reoperation, 1 not 
reoperated
Reoperation not 
successful
One reoperation not 
successful, 4 patients 
not reoperated
4 cured at reoperation: 
removal of an 
ipsilateral gland (3) 
and of 1 ipsi. and 1 
contralateral gland (1)
193 patients
with one 123I-99mTc-
sestamibi scan finding
2 uncured
patients with
no operation finding
at scan-guided site
Figure 2:The findings and outcome of surgery in 193 patients with a unilateral uptake on 99mTc-sestamibi/123I scintigraphy. TP: true positive
scintigraphy finding; that is, a pathological parathyroid gland was found at the scan-guided site at surgery. FP: false positive scintigraphy
finding; that is, no pathological glandwas found at the scan-guided site at surgery. FN: false negative scintigraphy finding; that is, a pathological
gland was identified at surgery despite no positive preoperative imaging finding at this site, or a patient was not cured despite the removal of
a gland identified by preoperative imaging.
Table 1: Characteristics of 269 patients with primary hyperparathy-
roidism (median with range or 𝑛 with percentage).
Median (range) or 𝑛 with
percentage
Age (years) 61 (16–91)
Gender: female/male 199 (74%)/70 (26%)
Serum ionized calcium (mmol/L) 1.49 (1.30–2.42)
Serum PTH (ng/L) 159 (53–3765)
Serum 25-OHD (nmol/L) (𝑛 = 224) 42.5 (13–99)
Serum creatinine (𝜇mol/L) 68 (42–330)
Urinary calcium (mmol/24 h)
(𝑛 = 252) 8.76 (0.23–29.38)
Number of focuses on
123I-99mTc-sestamibi scan (0/1/2%) 63/193/13 (23,4/71,7/4,8)
Number of focuses on
123I-99mTc-sestamibi scan (0/1/2%) 158/102/9 (58,7/37,9/3,3)
Weight of pathological gland (g)
(𝑛 = 188) 0.65 (0.037–22)
(54.9–66.8) for 99mTc-sestamibi/123I and 34.2% (28.5–40.2)
for 99mTc-sestamibi, respectively (𝑃 < 0.001). The corre-
sponding accuracies for MGD (= the scan correctly revealed
all pathological glands) were 14.6% (3.8–25.5) and 9.7% (0.6–
18.8), respectively (𝑃 < 0.001).
Table 2: Accuracies of preoperative localization studies.
Planar scintigraphy
with
99mTc-sestamibi
Planar scintigraphy
with
123I-99mTc-sestamibi
Overall accuracy
(95% CI) 34.9% (29.2–40.6) 63.4% (57.4–69.0)
Accuracy for one
scintigraphic finding 34.2% (28.5–40.2) 60.9% (54.9–66.8)
Accuracy in
multiglandular
disease∗
9.7% (0.6–18.8) 14.6% (3.8–25.5)
P value < 0.001 between 123I-99mTc-sestamibi and 99mTc-sestamibi-
scintigraphy.
∗The scan revealed correctly all pathological glands without false negative
findings.
3.2.2. Unilateral Uptake on 99𝑚𝑇𝑐-Sestamibi/123𝐼 Scintigra-
phy. Among 193 patients (71.7%) with one focus on 99mTc-
sestamibi/123I, the surgeon identified one pathological gland
at the scan-guided site in 183 patients, but only 164 of
these patients were cured after surgery because of addi-
tional diseased parathyroid glands (Figure 2). In 10 patients
with a unilateral 99mTc-sestamibi/123I finding, surgery was
extended but did not result in cure (Figure 2). In 19 of 193
(9.8%) patients there was a true positive finding but also
a false negative finding. Ten patients (5.2% of 193 cases)
had a single false positive uptake on 99mTc-sestamibi/123I
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mibi 5min p.i.
Parat dua1
123I 3.5h
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123I 6 h
Parat dua2
mibi 2.5h p.i.
Parat dua2
Figure 3: Parathyroid 99mTc-sestamibi-123I-subtraction scintigraphy in a 53-year-old woman with primary hyperparathyroidism (serum
ionized calcium 1.58mmol/l, PTH 201 ng/l).The patient was cured by removal of a 2.0-gram parathyroid adenoma excised at the site predicted
in the scintigraphy. First row: early 99mTc-sestamibi image (left), early 123I image (right). Second row: delayed 99mTc-sestamibi image (left),
delayed 123I image (right). Third row: the subtraction image of delayed 99mTc-sestamibi and 123I images shows a focal uptake at the inferior
pole of left thyroid gland and is seen only in this image.
(Figure 2). In altogether 29 of 193 patients (15%) 99mTc-
sestamibi/123I failed to accurately identify all pathological
glands (Figure 2). Twenty-two of these 29 patients were cured
either by extended primary surgery or reoperation. Other
inaccuracies included 10 patients with bilateral disease for
whom 99mTc-sestamibi/123I demonstrated only one unilateral
uptake and 9 patients with a single uptake on the wrong
side of the neck. In 3 cases primary surgery was unsuccessful
despite a correct finding on 99mTc-sestamibi/123I (confirmed
at reoperation). In 7 cases disease status remains open as
reoperation was unsuccessful or not performed (Figure 2).
Figure 3 demonstrates typical findings in a patients for whom
dual isotope scintigraphy was positive and single isotope
scintigraphy remained negative.
3.2.3. Bilateral Uptake on Preoperative 99𝑚𝑇𝑐-Sestamibi/123𝐼
Scintigraphy. Thirteen patients (4.8%) had bilateral uptake
on 99mTc-sestamibi/123I and 10 (76.9%) were cured. Eleven
underwent bilateral and two unilateral neck exploration.
Based on the operative findings at primary surgery, 99mTc-
sestamibi/123I was considered accurate in 6/13 (46.2%), but
the number rose to 9/13 (69.2%) based on reoperative find-
ings. Four of 13 patients who had single-gland disease but a
false positive finding on the other side of the neck were cured.
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Table 3: Scintigraphic results compared with histopathological findings in 265 patients who had pathological gland(s) removed.
Histopathology Patients 𝑛 Cured 𝑛 (%)
Number of
pathological
glands
Number (%) of positive
glands
on 123I-99mTc-sestamibi
scan
True positivesa 𝑛
(% of all glands) False positive
b (𝑛)
Single adenoma 218 206 (94) 218 176 (81) 165 (76) 11c
Multiple adenomas 3 3 6 3 (50) 3 (50) 0
Hyperplasia (one gland in
10d cases)
24 20 40 21 (52) 18 (45) 3
Hyperplasia or/and
adenoma (one gland in 9
cases)
15 15 22 12 (54) 11 (50) 1
Carcinoma 3 3 3 2 (67) 2 (67) 0
Carcinoma and
hyperplastic gland 2 2 5 3 (60) 3 (60) 0
aA true positive finding is defined as scintigraphic finding on the same side as the operative finding, and the finding is histologically confirmed.
bA false positive finding is defined as scintigraphic finding on the contralateral side compared to the operative finding.
cOf these 11 patients, 7 had bilateral imaging findings and 4 had one unilateral finding on the wrong side of the neck.
dOf the 10 patients with one hyperplastic gland removed at primary surgery, 4 were not cured as they had multiglandular disease, while 4 had single gland
disease and were cured.
Table 4: Characteristics (median with range) of cured patients with a single adenoma (𝑛 = 206) detected or not detected on preoperative
123I-99mTc-sestamibi scintigraphy.
Detected (𝑛 = 159) Not detected (𝑛 = 47) P value
Age (years) 61 (31–91) 63 (30–81) 0.57
Gender: female/male 116 (73%)/43 33 (58%)/14 0.71
Serum ionized calcium (mmol/L) 1.46 (1.3–2.24) 1.43 (1.3–1.74) 0.014
Serum PTH (g/L) 168 (71–1887) 133 (82–388) 0.0055
Serum 25-OHD (nmol/L) 44 (14–98) 48 (22–67) 0.68
Serum creatinine (mmol/L) 69 (45–225) 66 (46–137) 0.43
Urinary calcium (mmol/24 h) 9.02 (0.49–29.38) 8.00 (0.69–18.56) 0.37
Weight of adenoma (g) 0.78 (0.08–8.49) 0.35 (0.13–1.30) <0.001
3.2.4. Negative Preoperative 99𝑚𝑇𝑐-Sestamibi/123𝐼. 99mTc-
sestamibi/123I demonstrated no uptake in 63 patients
(23.4%), 56 of whom underwent bilateral exploration
(Figure 1). Surgery revealed one pathological gland in 57 of
the 63 patients, 54 of whom were biochemically cured. Four
of the 63 patients proved to have multiglandular disease and
were cured after bilateral exploration. Although no apparent
parathyroid tissue was removed in two of the 63 patients, one
of them was biochemically cured.
3.3. Comparison of Scintigraphic and Histopathological Find-
ings. Histopathology confirmed single adenoma in 218
patients. 99mTc-sestamibi/123I was accurate in 75.7% and
99mTc-sestamibi alone in 41.7% (𝑃 < 0.001) of cases (Table 3).
For the 47 patients with other histological diagnoses or two
or more abnormal glands (multiple adenomas, hyperplasia,
a combination of these, or carcinoma and hyperplasia),
37/76 (48.7%) pathological glands were accurately revealed
by 99mTc-sestamibi/123I. Five patients had parathyroid car-
cinoma (3 had carcinoma only and 2 had both parathyroid
carcinoma and hyperplasia). All parathyroid carcinomas
were visible on 99mTc-sestamibi/123I.
3.4. Multiglandular Disease. Sixteen patients were not cured
by removal of one abnormal parathyroid (12 adenomas, 4
hyperplastic glands) and were thus considered as having
multiglandular disease. In addition, two or more abnormal
glands were removed at primary surgery in 25 patients with
altogether 58 abnormal parathyroids. The rate of multiglan-
dular disease in the whole cohort was 15.2% (41/269 patients)
and per-patient based cure rate was 61.0% (25/41 patients).
3.5. Determinants of True Positive 99𝑚𝑇𝑐-Sestamibi/123𝐼 Find-
ings. Two hundred and six patients were cured by removal
of a single adenoma. Preoperative serum ionized calcium
and PTH concentrations were significantly higher in the 159
patients whose preoperative scan demonstrated one focus
compared to the 47 patients who had a negative scan (𝑃 <
0.02 and 𝑃 < 0.01, resp.; Table 4). Median weight of
the removed adenomas was twice higher in scan-positive
compared to scan-negative patients (𝑃 < 0.001; Table 4).
3.6. Duration of Surgery. The duration of surgery according
to the type of surgery performed is given in Table 5. Median
operation time for surgery targeted to one or two quadrants
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Table 5: The duration (min; median with range) of operative
procedure among 219 cured patients, who did not have simultaneous
thyroid surgery.
Type of surgery 𝑛 Duration
Unilateral, one quadrant∗ 105 46.2 (22.0–135.0)
Unilateral, two quadrants 44 52.4 (33.0–160.0)
Bilateral neck exploration 70 67.9 (33.0–181.2)
P value < 0.001 for comparison between the groups.
∗Comprising mini-invasive surgery.
was 21 and 15 minutes shorter compared to bilateral neck
exploration, respectively (both 𝑃 < 0.001). Targeted one-
quadrant surgery was 6 minutes shorter than unilateral neck
exploration (𝑃 < 0.001).
4. Discussion
The main finding of this single-centre retrospective series of
269 consecutive patients is that 99mTc-sestamibi/123I scintig-
raphy is significantly more accurate than 99mTc-sestamibi
scintigraphy alone (63% versus 34%) in the workup of PHPT
patients referred for primary surgery. The findings are in
line with some previous studies reporting better performance
of dual- compared to single-tracer techniques [8, 10–12].
However, these studies reported sensitivities (72%–94% ver-
sus 62%–79%) rather than accuracies [8, 10–12]. A recent
Finnish study comparing 5 different scintigraphy protocols
in 24 patients concluded that any dual-tracer protocol with
99mTc-sestamibi and 123I is superior to 99mTc-sestamibi alone
[13]. Philippon et al. compared the preoperative findings
of 99mTc-sestamibi/123I and 99mTc-sestamibi alone in 182
patients who underwent bilateral neck exploration because of
PHPT and reported accuracies of 50% and 32%, respectively
[14]. Wakamatsu et al. [15] reported a sensitivity of 39% for
99mTc-sestamibi alone. The findings of the present study are
in line with the recommendations of the EANM guidelines;
that is, an additional thyroid-specific isotope should be
used in order to get a pure thyroid image [2]. SPECT or
SPECT/CT has gained much popularity for localization of
pathological parathyroid glands, and CT allows for better
anatomical identification of the abnormal gland. However,
SPECT or SPECT/CT was not used in the present study.
However, we previously reported (Schalin-Ja¨ntti et al.) [16]
that, in PHPT, planar 99mTc-sestamibi/123I performs better
than 99mTc-sestamibi SPECT before reoperation. This is in
line with the study by Tunninen et al. [13] who found no
difference in sensitivity, specificity, or accuracy between the
acquisition techniques using dual-tracer technique (planar,
SPECT, or SPECT/CT imaging). The data indicate that using
dual isotopes instead of single isotope is more crucial than
planar, SPECT, or SPECT/CT imaging per se. Hassler et al.
[17] studied SPECT/CT and planar imaging with 99mTc-
sestamibi/123I and reported no significant difference in sen-
sitivities (86% and 75%, resp.) but significant difference in
specificities (100% and 90%, resp.).
In the present study, 99mTc-sestamibi remained negative
in up to one-quarter of the patients. In line with previous
results, patients with negative preoperative scintigraphy were
characterized by mild single-gland disease, mild increases in
serum calcium and PTH concentrations, and only slightly
enlarged pathological parathyroid glands [14, 15, 18–21].
Small tumour size and mild disease are therefore important
negative determinants of the preoperative scan.
It has been estimated that approximately 60–70% of
patients with PHPT are candidates for unilateral neck explo-
ration [15, 19–21]. In order to be of help, preoperative imag-
ing must unequivocally demonstrate single-gland disease
in patients scheduled for targeted surgery. Furthermore,
patients with familial PHPT or multiple endocrine neoplasia
must be excluded, as well as patients who have undergone
previous parathyroid or thyroid surgery. In the present series,
193 (71.5%) patients fulfilled these criteria. Targeted surgery
failed in 6% (12/166) of patients undergoing unilateral neck
exploration or a minimal invasive approach. If targeted
surgery had not been converted to bilateral neck exploration,
17 additional cases would have been unsuccessful. When
taking into account the results of later reoperations, overall
false positive and false negative rates of the 206 positive
preoperative 99mTc-sestamibi/123I scans in the present study
were 6.8% (14/206) and 9.2% (19/206), respectively. In com-
parison, in the large study by Civelek et al., using delayed
sestamibi-SPECT imaging only, a higher false positive rate of
14% (58/407) was reported [20].
In the present series, 16/19 patients with unsuccessful
surgery had multiglandular disease, and, in line with the
study by Hindie´ et al. [22], the rate of multiglandular PHPT
was at least 15%. Siperstein et al. [23] reported an even
higher percentage of 22 in a series of 1158 patients with a
single finding on sestamibi imaging, all of whom underwent
bilateral neck exploration in addition to targeted surgery.
Compared to the 99mTc-sestamibi single-tracer technique
[18], higher sensitivities for subtraction imaging have been
reported also for multiglandular disease, exceeding 80%
in a study by Hindie´ et al. [22]. In the present series,
43.8% of the total number of positive 99mTc-sestamibi/123I
findings in multiglandular disease were true positive. Thus,
a serious limitation of preoperative imaging for PHPT is
failure to accurately identify multiglandular disease. Shen et
al. concluded that their surgical failure rate would be as high
as 10% if surgery was based on sestamibi scan imaging instead
of routine bilateral neck exploration [24]. Furthermore, Nor-
man et al. reported recurrent disease in at least 5% during 10-
year follow-up of patients initially held as cured by primary
unilateral surgery [25]. In contrast, the results of primary
bilateral neck exploration did not change over time [25].
In accordance with previous studies [26], 99mTc-
sestamibi/123I scintigraphy did not improve outcome of
surgery in the present series. However, a single positive
finding aids the surgeon in selecting the correct patients
for targeted surgery. Limited exploration enables shorter
operation time [26–28] and is generally associated with
lower complication rates. Most surgeons appreciate
having preoperative information regarding which side
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of the neck dissection should be initiated. The third
international workshop on surgery for PHPT concluded
that the main advantage of sestamibi scans is the ability to
localize parathyroid glands in ectopic sites, including the
mediastinum [29]. It was also concluded that surgery should
not be ruled out based on a negative preoperative scan [29].
Although most previous localization studies relate operative
success primarily to the sensitivity of the preoperative
imaging technique, choice of surgery is another important
determinant. In the present study, the reading of the scan
changed in 5% upon reevaluation. Great care should thus
also be given to adequate reading of the scans.
In conclusion, this large retrospective series demon-
strates that 99mTc-sestamibi/123I is more accurate than 99mTc-
sestamibi alone in the preoperative workup of PHPT. How-
ever, performing scintigraphy is not equal to improving
surgical outcome. Not even 99mTc-sestamibi/123I performs
well in multiglandular disease, which is present in about 15%
of patients referred for primary surgery of PHPT.
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